ZeoliteSupport

Enclosed is an announcement that the FDA sanctioned scientific study using zeolite with autistic children has been approved. May many benefit from the information obtained.

Natural Cellular Liquid Zeolite (zeolite), a safe, natural, inert mineral supplement has generated many encouraging reports from parents of autistic children. Zeolite has attracted the interest of some of the leading autism researchers and physicians. A randomized, double-blind, placebo-controlled study designed to evaluate the benefits of Zeolite on Autism Spectrum Disorders was approved by BioMed IRB on June 7, 2006.

San Diego, California - June 7, 2006

BioMed IRB of San Diego, California has approved a clinical trial that seeks to evaluate the benefits of adding a patented supplement, zeolite zeolite, to the diet of children diagnosed with Autism Spectrum Disorders. Natural Cellular Liquid Zeolite is purified clinoptilolite, a type of zeolite, suspended in solution. The zeolite is purified using a patented process and named zeolite.

This form of zeolite is one of the few negatively charged minerals in nature, and it has a microscopic honeycomb-like crystalline structure of cavities and cages. Animal studies show that they have the ability to attract, trap, bind and remove various heavy metals and toxins such as mercury, lead and arsenic.

The study's eighty autistic children will be divided into two groups. One group is receiving the zeolite and the other the placebo for ninety days. Both groups will be measured using a variety of established instruments for autism diagnosis and treatment evaluation. Further, since other animal and human studies with zeolite have demonstrated the ability for zeolite to remove heavy metals, a portion of the participants will receive a series of urine excretion tests designed to detect levels of heavy metal excretion. If previous studies in adults hold true for these autistic children, the researchers may see excretion rates as high as 10 times over their baseline.

At the end of the ninety day study period, those receiving the placebo will then begin taking the zeolite and be tracked for ninety more days.

Two sites have been approved so far. In Plano, Texas, Dr. Seshagiri Rao, a Board Certified Pediatrician is the lead investigator. The second site, in Baton Rouge, Louisiana is lead by Dr. Stephanie Cave. Both sites have begun recruiting for study participants.

Professor James Adams, PhD will conduct the study data analysis. Dr. Adams has reviously published studies on the high level of mercury toxicity common in many autistic children. Other studies suggest a possible link between Thirmersol concentration found in many vaccines and the high mercury levels in autistic children.